{'fraction_non_alphanumeric': 0.02275189599133261, 'fraction_numerical': 0.0065005417118093175, 'mean_word_length': 5.503521126760563, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
NOTCH signaling limits the response of Low Grade Serous Ovarian Cancers to MEK inhibition.

Low-grade serous ovarian cancer (LGSOC) is a rare subtype of epithelial ovarian cancer with high fatality rates in advanced stages due to its chemo-resistant properties. LGSOC is characterized by activation of MAPK signaling and recent clinical trials indicate that the MEK inhibitor (MEKi) trametinib may be a good treatment option for a subset of patients. Understanding MEKi resistance mechanisms and subsequent identification of rational drug combinations to suppress resistance may greatly improve LGSOC treatment strategies. Both gain-of-function and loss-of-function CRISPR-Cas9 genome-wide libraries were used to screen LGSOC cell lines to identify genes that modulate the response to MEKi. Overexpression of MAML2 and loss of MAP3K1 were identified, both leading to overexpression of the NOTCH target HES1, which has a causal role in this process as its knockdown reversed MEKi resistance. Interestingly, increased HES1 expression was also observed in selected spontaneous trametinib resistant clones, next to activating MAP2K1 (MEK1) mutations. Subsequent trametinib synthetic lethality screens identified SHOC2 downregulation as being synthetic lethal with MEKi. Targeting SHOC2 with pan-RAF inhibitors (pan-RAFi) in combination with MEKi was effective in parental LGSOC cell lines, in MEKi resistant derivatives, in primary ascites cultures from LGSOC patients and in LGSOC (cell line derived and patient-derived) xenograft mouse models. We found that the combination of pan-RAFi with MEKi downregulated HES1 levels in trametinib resistant cells, providing an explanation for the synergy that was observed. Combining MEKi with pan-RAFi may provide a promising treatment strategy for LGSOC patients, which warrants further clinical validation.